ND PHARMA & BIOTECH OPEN DEALS FOR LICENSE OF ITS NEW ALZHEIMER´S DRUG NOOPEPTIL

San Francisco.CA.
ND Pharma & Biotech has a novel neuroprotective drug NOOPEPTIL, that is in commercialization authorization phase within  different countries worldwide, awaiting the decision of some regulators. This novel racetam analogue, is composed by a mixture of two novel dipeptide-amide molecules, with a standard power of +300 times of actual molecules as Piracetam with advantage of being 10.000 times less toxic. The potential of this new drug has been evaluated largely during the phases of development and several independent clinical studies were performed from different groups of researchers and scientists worldwide. 
Noopeptil, has some activity over other conditions as it was claimed and approved on the IP and patent established rights that will be evolved to adapt the drug commercial presentation to new indications as extension of the actual existent and approved.
3 first Line industries from Big Pharma Industry has approached to ND Pharma & Biotech Regulation Department to initiate conversations and negotiate the licenses to the different countries where they are gaining positions to the launching of such novel product, with special indication on initial and mild stage of neuro-cognoscitive deterioration, memory loss and Alzheimer´s disease.